PMID- 35999281
OWN - NLM
STAT- MEDLINE
DCOM- 20221108
LR  - 20221202
IS  - 1348-4214 (Electronic)
IS  - 0916-9636 (Linking)
VI  - 45
IP  - 11
DP  - 2022 Nov
TI  - Dose-response association between plasma homocysteine and white matter lesions in 
      patients with hypertension: a case-control study.
PG  - 1794-1801
LID - 10.1038/s41440-022-00999-w [doi]
AB  - White matter lesions (WMLs) are common MRI changes that are indicative of 
      cerebral small vessel disease (CSVD). Elevated plasma homocysteine (Hcy) levels 
      are related to an increased risk of vascular disease. We aimed to analyze the 
      relationship between Hcy levels and WMLs in patients with hypertension. A total 
      of 1961 patients with WMLs and 15,463 patients without WMLs were matched at a 1:1 
      ratio by age and sex. Hyperhomocysteinemia (HHcy) was defined as an abnormally 
      high level (>15 micromol/l) of Hcy in a plasma sample. In total, 1888 (WML group) and 
      1888 (No-WMLs group) patients were enrolled, with 51.6% of the sample being male 
      and a mean age of 63 years. Multivariate logistic regression analysis showed a 
      significant association between a higher level of plasma Hcy and a higher 
      prevalence of WMLs (OR 1.03 95% CI, 1.02-1.04) when the Hcy level was used as a 
      continuous variable. Patients with Hcy levels of 15-20 micromol/l (OR 1.54, 95% CI 
      1.31-1.81) and >20 micromol/l (OR 1.51, 95% CI 1.26-1.82) also had a significantly 
      higher risk of WMLs than patients with Hcy levels <15 micromol/l. 
      Multivariable-adjusted spline regression models showed that the risk of WMLs 
      started to increase only in patients with Hcy levels above 13.85 micromol/l 
      (P < 0.001). In subgroup analyses of WMLs, there was no significant interaction 
      between the Hcy group and subgroup heterogeneity for the prevalence of WMLs 
      (P > 0.05). Our study found a dose-response association between plasma 
      homocysteine levels, especially a Hcy level >13.85 micromol/l, and the prevalence of 
      WMLs, implying that lowering Hcy levels might be a target for prevention.
CI  - (c) 2022. The Author(s), under exclusive licence to The Japanese Society of 
      Hypertension.
FAU - Yuan, Yujuan
AU  - Yuan Y
AD  - Xinjiang Medical University, Urumqi, China.
FAU - Cai, Xintian
AU  - Cai X
AD  - Xinjiang Medical University, Urumqi, China.
FAU - Liu, Yan
AU  - Liu Y
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region "Hypertension Research Laboratory, Xinjiang Clinical Medical Research 
      Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China.
FAU - Li, Nanfang
AU  - Li N
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region "Hypertension Research Laboratory, Xinjiang Clinical Medical Research 
      Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China. 
      lnanfang2016@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20220823
PL  - England
TA  - Hypertens Res
JT  - Hypertension research : official journal of the Japanese Society of Hypertension
JID - 9307690
RN  - 0LVT1QZ0BA (Homocysteine)
SB  - IM
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Female
MH  - Case-Control Studies
MH  - Homocysteine
MH  - *White Matter/diagnostic imaging
MH  - *Hyperhomocysteinemia/complications
MH  - *Hypertension/complications
OTO - NOTNLM
OT  - Cerebral small vessel disease
OT  - Homocysteine levels
OT  - Hypertension
OT  - White matter lesions
EDAT- 2022/08/24 06:00
MHDA- 2022/11/09 06:00
CRDT- 2022/08/23 23:20
PHST- 2022/03/03 00:00 [received]
PHST- 2022/07/07 00:00 [accepted]
PHST- 2022/06/05 00:00 [revised]
PHST- 2022/08/24 06:00 [pubmed]
PHST- 2022/11/09 06:00 [medline]
PHST- 2022/08/23 23:20 [entrez]
AID - 10.1038/s41440-022-00999-w [pii]
AID - 10.1038/s41440-022-00999-w [doi]
PST - ppublish
SO  - Hypertens Res. 2022 Nov;45(11):1794-1801. doi: 10.1038/s41440-022-00999-w. Epub 
      2022 Aug 23.